BiotechTube

Eptinezumab + Placebo

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cluster Headache, Episodic

Conditions

Cluster Headache, Episodic

Trial Timeline

Dec 23, 2020 → Oct 5, 2023

NCT ID
NCT04688775

About Eptinezumab + Placebo

Eptinezumab + Placebo is a phase 3 stage product being developed by Lundbeck for Cluster Headache, Episodic. The current trial status is completed. This product is registered under clinical trial identifier NCT04688775. Target conditions include Cluster Headache, Episodic.

What happened to similar drugs?

1 of 6 similar drugs in Cluster Headache, Episodic were approved

Approved (1) Terminated (0) Active (5)
🔄Galcanezumab 300 mg + PlaceboEli LillyPhase 3
🔄GalcanezumabEli LillyPhase 3
🔄Galcanezumab + PlaceboEli LillyPhase 3
🔄Bosutinib + ImatinibPfizerPhase 3
🔄EptinezumabLundbeckPhase 3
✅MethylprednisoloneBrain BiotechApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT05897320Phase 3Recruiting
NCT05452239ApprovedCompleted
NCT04965675Phase 3Recruiting
NCT04688775Phase 3Completed
NCT04418765Phase 3Completed
NCT04336449Phase 1Completed
NCT04152083Phase 3Completed

Competing Products

8 competing products in Cluster Headache, Episodic

See all competitors
ProductCompanyStageHype Score
Galcanezumab 300 mg + PlaceboEli LillyPhase 3
40
GalcanezumabEli LillyPhase 3
40
Galcanezumab + PlaceboEli LillyPhase 3
40
candesartan cilexetil + placeboAstraZenecaPhase 2
35
SOM230 + PlaceboNovartisPhase 2
27
Bosutinib + ImatinibPfizerPhase 3
40
EptinezumabLundbeckPhase 3
37
MethylprednisoloneBrain BiotechApproved
33